Remington: The Science and Practice of Pharmacy

The PCP's Bicentennial Edition

Remington: The Science and Practice of Pharmacy, Twenty Third Edition, offers a trusted, completely updated source of information for education, training, and development of pharmacists. Published for the first time with Elsevier, this edition includes coverage of biologics and biosimilars as uses of those therapeutics have increased substantially since the previous edition. Also discussed are formulations, drug delivery (including prodrugs, salts, polymorphism. With clear, detailed color illustrations, fundamental information on a range of pharmaceutical science areas, and information on new developments in industry, pharmaceutical industry scientists, especially those involved in drug discovery and development will find this edition of Remington an essential reference. Intellectual property professionals will also find this reference helpful to cite in patents and resulting litigations. Additional graduate and postgraduate students in Pharmacy and Pharmaceutical Sciences will refer to this book in courses dealing with medicinal chemistry and pharmaceutics.

• Contains a comprehensive source of principles of drug discovery and development topics, especially for scientists that are new in the pharmaceutical industry such as those with trainings/degrees in chemistry and engineering
• Provides a detailed source for formulation scientists and compounding pharmacists, from produg to excipient issues
• Updates this excellent source with the latest information to verify facts and refresh on basics for professionals in the broadly defined pharmaceutical industry

Adeboye Adejare’s research group is interested in the areas of design and syntheses of small organic molecules to probe neurodegeneration, especially Alzheimer’s disease, and for treatment of cancer. They are also interested in in vitro models of drug absorption and ability to cross blood brain barrier; drug targeting; pharmaceutical profiling; and chemistry of fluoroaromatic compounds. The research is funded by the National Institutes of Health, the Office of Naval Research, and several pharmaceutical companies. These efforts have resulted in over 50 publications, 5 patents, and over 100 presentations at meetings, including invited presentations at national and international conferences. He also serves on several national panels, including those by NIH, NSF, and Alzheimer’s Association.

Dr. Adejare is the editor of Drug Discovery Approaches for the Treatment of Neurodegenerative Disorders: Alzheimer’s Disease which is also published by Elsevier.